Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Low-dose CT Lung Cancer Screening Nets Payoff in Community Setting

Publish date:: June 18, 2019

Key clinical point: Implementation of low-dose CT screening in the community is achieving diagnosis of lung cancer at an early, more treatable stage.

Major finding: More than 50% of lung cancers were diagnosed at stage I or limited stage in community and academic centers.

Study details: A cross-sectional survey of 165 lung cancer screening centers designated as Screening Centers of Excellence (62% community based) asking about 2016 program data and practices.

Disclosures: Dr. King reported that she receives honoraria from MedImmune, AstraZeneca, and Genentech; has a consulting or advisory role with GRAIL, Tesaro, AbbVie, and Foundation Medicine; and receives research funding from AstraZeneca. The study was supported by the GO2 Foundation for Lung Cancer.

Citation:

King JC et al. J Oncol Pract. 2019 May 31. doi: 10.1200/JOP.18.00788.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Lung Cancer

Two different radiation boost strategies reduce local failures in NSCLC,

Rechallenge ‘reasonable’ for some with small-cell lung cancer,

Black patients with ES-SCLC get less chemo but have better survival,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Reduced cancer mortality with Medicaid expansion,